Article
High-affinity CD16A polymorphism associated with reduced risk ofsevere COVID-19.
JCI insight - 8 Jul 2025
Qualls Anita E, Tsao Tasha, Lui Irene, Lim Shion A, Su Yapeng, Chen Ernie, Duchen Dylan, Maecker Holden T, Kim-Schulze Seunghee, Montgomery Ruth R, Krammer Florian, Langelier Charles R, Levy Ofer, Baden Lindsey R, Melamed Esther, Ehrlich Lauren Ir, McComsey Grace A, Sekaly Rafick P, Cairns Charles B, Haddad Elias K, Shaw Albert C, Hafler David A, Corry David B, Kheradmand Farrah, Atkinson Mark A, Brakenridge Scott C, Higuita Nelson I Agudelo, Metcalf Jordan P, Hough Catherine L, Messer William B, Pulendran Bali, Nadeau Kari C, Davis Mark M, Fernandez-Sesma Ana, Simon Viviana, Kraft Monica, Bime Christian, Calfee Carolyn S, Erle David J, Schaenmann Joanna, Ozonoff Al, Peters Bjoern, Kleinstein Steven H, Augustine Alison D, Diray-Arce Joann, Becker Patrice M, Rouphael Nadine, Goldman Jason D, Calabrese Daniel R, Heath James R, Wells James A, Reed Elaine F, Lanier Lewis L, Pickering Harry, Aguilar Oscar A
Abstract excerpt
CD16A is an activating Fc receptor on NK cells that mediates antibody-dependent cellular cytotoxicity (ADCC), a key mechanism in antiviral immunity. However, the role of NK cell-mediated ADCC in SARS-CoV-2 infection remains unclear, particularly whether it limits viral spread and disease severity or contributes to the immunopathogenesis of COVID-19. We hypothesized that the high-affinity CD16AV176 polymorphism...
Read the complete abstract on PubMed